Inactivation of XPF Sensitizes Cancer Cells to Gemcitabine
Gemcitabine (2′, 2′-difluorodeoxycytidine; dFdC) is a deoxycytidine analog and is used primarily against pancreatic cancer. The cytotoxicity of gemcitabine is due to the inhibition of DNA replication. However, a mechanism of removal of the incorporated dFdC is largely unknown. In this report, we dis...
Main Authors: | Joseph W. George, Mika Bessho, Tadayoshi Bessho |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2019-01-01
|
Series: | Journal of Nucleic Acids |
Online Access: | http://dx.doi.org/10.1155/2019/6357609 |
Similar Items
-
Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation
by: Tang Yong, et al.
Published: (2012-09-01) -
Acetylation of XPF by TIP60 facilitates XPF-ERCC1 complex assembly and activation
by: Jiajia Wang, et al.
Published: (2020-02-01) -
Effects of FUX on gemcitabine sensitivity in lung cancer cells
by: Lu, Wei
Published: (2015) -
XPF expression and its relationship with the risk and prognosis of colorectal cancer
by: Huixin Hu, et al.
Published: (2021-01-01) -
Selective killing of homologous recombination-deficient cancer cell lines by inhibitors of the RPA:RAD52 protein-protein interaction.
by: Mona Al-Mugotir, et al.
Published: (2021-01-01)